Demylocan 50 mg (Decitabine POWDER) 50 MG

Demylocan 50 mg is a powder form of decitabine used for intravenous administration. This medication is commonly associated with certain types of cancer treatments. Learn more about its uses and effects.

Strength

50 MG

Manufacturer / TM Owner

PENDOPHARM DIVISION OF PHARMASCIENCE INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Demylocan 50 mg, containing the active ingredient decitabine, is primarily used in the treatment of specific types of cancer. It works by affecting the growth of cancer cells, making it a critical component in certain chemotherapy regimens. Patients often wonder, 'What is Demylocan used for?' and the answer lies in its role as an antineoplastic agent.

Side Effects

Common effects of Demylocan 50 mg may include fatigue, nausea, and low blood cell counts. These effects can vary from person to person and are typically managed under medical supervision. It's important to discuss any concerns with a healthcare provider.

Precautions & Warnings

Handling Demylocan 50 mg requires careful attention to dosage and administration guidelines. It should only be used under the supervision of a healthcare professional. Patients with certain medical conditions or allergies should inform their doctor before starting treatment.

Avoid Interactions

Demylocan 50 mg may interact with other medications, including those that affect the immune system or blood cell production. It's crucial to inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

Demylocan 50 mg is used in the treatment of certain types of cancer, primarily as part of chemotherapy regimens.

Demylocan 50 mg is administered intravenously, typically in a clinical setting under medical supervision.

Common side effects may include fatigue, nausea, and low blood cell counts. Always consult a healthcare provider for personalized advice.

Demylocan 50 mg may interact with other medications, so it's important to discuss all current medications with a healthcare provider.

Individuals with certain medical conditions or allergies should consult a healthcare provider before using Demylocan 50 mg.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.